U.S. Markets closed

Glenmark Pharmaceuticals Limited (GLENMARK.NS)


NSE - NSE Real Time Price. Currency in INR
Add to watchlist
696.30-12.00 (-1.69%)
At close: 3:30PM IST

Glenmark Pharmaceuticals Limited

Glenmark House
B D S Marg
Mumbai 400099
India
91 22 4018 9999
http://www.glenmarkpharma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Glenn Mario SaldanhaChairman, Chief Exec. Officer and Managing Director108.46MN/A47
Mrs. Cherylann Maria Pinto B.PharmExec. Director of Corp. Affairs and Exec. Director33.37MN/A50
Mr. P. GaneshPres and Global Chief Fin. OfficerN/AN/AN/A
Dr. Fred Grossman D.O., FAPAPres and Chief Medical OfficerN/AN/AN/A
Mr. Kanish MalikPres and Global Head of OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, Latin America, Europe, the United States, and internationally. The company provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system, dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, respiratory, cardiovascular, anti- diabetic, and oncology. Its products include Crofelemer for HIV related diarrhea; and is in Phase III clinical trials for adult acute infectious diarrhea, including cholera. The company’s products under development comprise GRC 17536 that is in Phase II clinical trial for neuropathic pain and respiratory disorders; GRC 15300, which is in Phase II clinical trial for neuropathic pain; GBR 830 for autoimmune disorders; GBR 900 for chronic pain; and Vatelizumab (GBR 500), a biological molecule for multiple sclerosis. The company was founded in 1977 and is headquartered in Mumbai, India.

Corporate Governance

Glenmark Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.